Maple Leaf Extract for Corneal Angiogenesis and Hyperemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for corneal and conjunctival diseases, such as hyperemia and corneal angiogenesis, often come with side effects like hemorrhage, retinal detachment, and increased intraocular pressure, necessitating safer and more effective alternatives.
Innovation Solution
A pharmaceutical composition containing a maple leaf extract, which is administered to the eyeball, has been developed to inhibit hyperemia and corneal angiogenesis without side effects, using methods like ethanol or hot-water extraction of maple leaves and fractionation to create effective formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal drugs are injected into the vitreous body to treat corneal angiogenic disease, then the disease is treated, but side effects such as hemorrhage, retinal detachment, and increased intraocular pressure occur
Solution Approach 1:
The patent uses a maple leaf extract as an intermediary substance to treat corneal angiogenic disease. Instead of directly injecting steroidal drugs that cause harmful side effects, the maple leaf extract serves as a natural mediator that provides therapeutic effects without the adverse reactions associated with conventional steroidal treatments. The extract contains active compounds that inhibit angiogenesis while avoiding the harmful effects of synthetic steroids.
Solution Approach 2:
The patent changes the chemical and pharmacological parameters of the treatment by using a natural maple leaf extract instead of synthetic steroidal drugs. This parameter change involves switching from a class of drugs with known harmful side effects to a natural extract with different chemical composition and pharmacological properties, thereby maintaining therapeutic effectiveness while eliminating the harmful effects.
2Duration of action of stationary object
If repeated injections of steroidal drugs are administered, then corneal angiogenic disease is treated, but cataract develops and intraocular pressure rises
Solution Approach 1:
The maple leaf extract acts as a safe intermediary that can be administered repeatedly without accumulating harmful effects. Unlike steroidal drugs that cause cataracts and pressure increases with repeated use, the natural extract provides sustained therapeutic effects through its anti-angiogenic properties without the toxic accumulation associated with repeated steroid injections.
Solution Approach 2:
The patent employs a natural maple leaf extract that can be administered multiple times without causing long-term harmful effects. The extract serves as a disposable, safe treatment option that eliminates the need to reduce dosage or stop treatment to avoid accumulating side effects like cataracts and intraocular pressure increases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The maple leaf extract effectively prevents or treats corneal and conjunctival diseases by inhibiting hyperemia and corneal angiogenesis in a dose-dependent manner, as demonstrated in rat models, offering a safer alternative to existing treatments.
Implementation Method 1
a maple leaf extract has inhibitory effects against hyperemia and corneal angiogenesis
Implementation Method 2
a maple leaf extract has inhibitory effects against hyperemia and corneal angiogenesis
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.